VTRO (Vitro Biopharma) Total Receivables: $0.07 Mil (As of Oct. 2022)


What is Vitro Biopharma Total Receivables?

Vitro Biopharma VTRO Total Receivables is $0.07 Mil as of Oct. 2022. The stock has 6 warning signs investors should review.

Vitro Biopharma's Total Receivables for the quarter that ended in Oct. 2022 was $0.07 Mil.

Vitro Biopharma Total Receivables Related Terms

Vitro Biopharma Total Receivables Historical Data

* Premium members only.

The historical data trend for Vitro Biopharma's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitro Biopharma Total Receivables Chart

Vitro Biopharma Annual Data
Trend Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.02 0.04 0.13 0.07

Vitro Biopharma Quarterly Data
Oct00 Oct01 Oct02 Oct03 Oct04 Oct05 Oct06 Oct07 Oct08 Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.04 0.13 0.07

Vitro Biopharma Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.07 Mil mean?
Vitro Biopharma (VTRO) has a Total Receivables of $0.07 Mil as of Oct. 2022. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Vitro Biopharma and its competitors.
Is Vitro Biopharma's Total Receivables too high?
Vitro Biopharma's current Total Receivables is $0.07 Mil.
How does Vitro Biopharma's Total Receivables compare to ?
Vitro Biopharma's Total Receivables of $0.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Vitro Biopharma and its competitors. Vitro Biopharma's current Total Receivables is $0.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitro Biopharma stock overvalued right now?
Vitro Biopharma (VTRO) has a current Total Receivables of $0.07 Mil. The current Total Receivables is $0.07 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current Total Receivables is $0.07 Mil as of Oct. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitro Biopharma Business Description

Comparable Companies
Address 4621 Technology Drive, Golden, CO, USA, 80403
Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.